What the 2026 midterms mean for medical marketing

For today’s program we are talking all about the midterms. A historically good night for Democrats could portend rough seas ahead for pharma brands.

Undoubtedly, the healthcare focus of the incoming Congress will be on affordability and cost concerns.

We’re diving into what the midterm results will likely mean for the healthcare industry, from additional drug pricing reforms to bolstering the ACA to establishing safeguards to prevent more cuts to Medicare.

We’re also going to explore the MAHA disappearing act, as the health movement failed to deliver on its vaunted political promise.

Also, could we see a return of the Medicare for All discourse?

But before we get into that, editor-at-large Steve Madden brings us a conversation with Eversana CEO Mark Thierer about its recent acquisition of Estima Scientific.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.